Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Abstract

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory <i>FLT3</i>-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).